© Topadur Pharma AG | May 2018 INNOVATIVE DRUGS FOR SEVERE  WOUND-HEALING  PROBLEMS  IN HOSPITALS Reto Naef, PhD, MBA CEO and founder © Topadur Pharma AG | May 2018

two future equity rounds expected exit: 2021 NEXT MILESTONES The company Founded: 2009 GmbH, 2015 AG Employees: 15 FINANCIALS 8.5 Mio equity 1.6 non diluting + 3.2 open two future equity rounds expected exit: 2021 NEXT MILESTONES TOP-N53 end toxicology Q2/18 IND Q3/18 FIH Q4/18 POC Q2/19 Problem & solution: Chronic non-healing wounds and excessive scar formation © Topadur Pharma AG | May 2018

© Topadur Pharma AG | May 2018 Key people committed to solve the problem Leadership and board >150 years Pharma R&D Leadership Board Dr. Guido Koch COO & Development Dr. Reto Naef CEO &President Dr. Reinhard Ambros Prof. Dr. Günther Wess VC, BD&L Helmholz, R&D, diabetes Dr. Hermann Tenor Medical R&D Christina Attaalla Finance, HR, Legal Dr. Armin Meinzer Secretary o. B. Dr. Dominik Escher Serial founder, deal making Pascal Brenneisen HP, investor, legal, market © Topadur Pharma AG | May 2018

Diabetic foot ulcer & chronic wounds What is the problem? Diabetic foot ulcer & chronic wounds Leading cause of hospitalizations in diabetes Insufficient local blood circulation 50 million patients hospitalized p.a. Huge cost burden ($12 bn p.a.) Market will double in 15 years Current Therapies (limited success) Negative pressure Skin substitutes Oxygen Growth factors Regranex (Becaplermin) 1 million foot amputations p.a. 5 year survival 21% © Topadur Pharma AG | May 2018

© Topadur Pharma AG | May 2018 Unique efficacy & excellent tolerability Our leading drug in development TOP-N53 Increases local blood flow in an unprecidented manner Convincing results in preclinical wound healing models Unique potency and efficacy No visible side effects in animals Clinical trial starting November 2018 Blockbuster potential © Topadur Pharma AG | May 2018

Regenerative medicine Past and future milestones The business case TOP-N53 DFU project and clinical strategy TOPADUR Big Pharma Drug Discovery Ongoing grant applications 3.5 Mio. CHF May 18 2009 2015 2018 2019 2021 TOPADUR Rare diseases Regenerative medicine © Topadur Pharma AG | May 2018

Scar & keloid prevention Topadur’s R&D portfolio Development drug pipeline and platform Wound healing TOP-N53 Scar & keloid prevention TOP-N44 Out licensing TOP-N73 Diabetic foot ulcers Orphan ulcera Decubitus Major surgery (incl. bone) Dental surgery Patent filed Nov 2015 Burn wounds Skin fibrosis Scleroderma Cosmetic surgery Patent to be filed Q1 2019 1. Glaucoma (Vistadur) 2. ED - Topical 3. Pulmonary Arterial Hypertension 4. Medical Cosmetics Patent filed March 2017 2nd Patent to be filed <July 2018 © Topadur Pharma AG | May 2018

© Topadur Pharma AG | May 2018 The drug and the patient groups Overview DFU Wagner classification Reduce # of amputations (> 1 Mio/year) Grade 0 No open lesion Grade 1 superficial lesion Grade 2 Deep ulcer Grade 3 abcess, osteomyelitis Grade 4 Partial foot gangreen Grade 5 Whole foot gangreen Topical TOP-N53 SR Hydrogel TOP-N53 SR Injectable © Topadur Pharma AG | May 2018

© Topadur Pharma AG | May 2018 Financial overview Financing Strategy In vitro profile 2 POC animal first in human POC Phase 1/2 Exit Trade sale IPO Orphan 1st launch DFU Phase 3 1st launch TCHF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Non-diluting financing Out-licensing 500 1’000 3’500 4’000 190’000 50’000 FTEs 4 8 12 13 14 20 30 45 70 General expenses -200 -1’800 -3’500 -3’800 -6’400 -8’800 -13’200 19’800 29’700 -44’500 Equity financing 300 2’200 6’100 (3’000)* 10’000 (13’000)** Company valuation 0.1-2 7-10 19-25 ... * 3-4 Mio. Convertable loan after completed toxicology program mid 2018 Depending on non diluting financing ** © Topadur Pharma AG | May 2018

© Topadur Pharma AG | May 2018 New venture Topadur ophthalmic project Vistadur Reduced occular blood flow Segment Current market Mio $ CAGR% AMD 7’800 8 Glaucoma 6’500 11 Diabetic retinopathy 2’300 6 Not-treatable Vistadur targets for drug intervention treatable © Topadur Pharma AG | May 2018

© Topadur Pharma AG | May 2018 Summary TOP-N53: Unique potency and efficacy, new dual mode of action Full pipeline Experienced leadership team and board Productive collaborations with academic leaders in their field Enormous market potential © Topadur Pharma AG | May 2018

DIABETES FOOT BURN WOUNDS TOP-N73 OUT LICENSING TOP-N53 TOP-N44 DIABETES FOOT BURN WOUNDS TOP-N73 OUT LICENSING HEALTH IS THE MOST IMPORTANT THING © Topadur Pharma AG | May 2018